Piramal Pharma Limited has informed the Exchange regarding a press release dated January 28, 2026, titled "Piramal Pharma Limited Announces Results for Q3 and 9M FY26".
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Piramal Pharma Limited has shared a press release dated January 28, 2026, announcing its financial results for the third quarter (Q3) and nine months (9M) of financial year 2026. The filing with the exchange is procedural — the detailed numbers will be in the company's Q3 FY26 results announcement. Investors should refer to the accompanying results document for revenue, profit, and segment-wise performance figures. The company typically reports across its CDMO, complex hospital generics, and consumer healthcare segments.
The actual market impact will depend on the numbers reported in the results, especially growth in the CDMO and consumer healthcare segments versus expectations. Shareholders should review the detailed results for any surprises in margins, order book updates, or guidance.